Stock Analysis
IntegraGen (EPA:ALINT) Full Year 2023 Results
Key Financial Results
- Revenue: €12.8m (down 2.9% from FY 2022).
- Net loss: €171.4k (loss widened by €167.9k from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IntegraGen shares are up 3.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for IntegraGen (1 is potentially serious!) that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether IntegraGen is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ENXTPA:ALINT
IntegraGen
Provides researchers with sequencing solutions, data management tools, and biostatistical, and bioinformatics support services in France.
Mediocre balance sheet and slightly overvalued.
